These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28698321)

  • 1. Factors associated with non-persistence to oral and inhaled antiviral therapies for seasonal influenza: a secondary analysis of a double-blind, multicentre, randomised clinical trial.
    Flicoteaux R; Protopopescu C; Tibi A; Blanchon T; Werf SV; Duval X; Mosnier A; Charlois-Ou C; Lina B; Leport C; Chevret S
    BMJ Open; 2017 Jul; 7(7):e014546. PubMed ID: 28698321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.
    Duval X; van der Werf S; Blanchon T; Mosnier A; Bouscambert-Duchamp M; Tibi A; Enouf V; Charlois-Ou C; Vincent C; Andreoletti L; Tubach F; Lina B; Mentré F; Leport C;
    PLoS Med; 2010 Nov; 7(11):e1000362. PubMed ID: 21072246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.
    Marty FM; Vidal-Puigserver J; Clark C; Gupta SK; Merino E; Garot D; Chapman MJ; Jacobs F; Rodriguez-Noriega E; Husa P; Shortino D; Watson HA; Yates PJ; Peppercorn AF
    Lancet Respir Med; 2017 Feb; 5(2):135-146. PubMed ID: 28094141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.
    Petersen E; Keld DB; Ellermann-Eriksen S; Gubbels S; Ilkjær S; Jensen-Fangel S; Lindskov C
    Scand J Infect Dis; 2011 Jul; 43(6-7):495-503. PubMed ID: 21309638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks.
    Anekthananon T; Pukrittayakamee S; Ratanasuwan W; Jittamala P; Werarak P; Charunwatthana P; Suwanagool S; Lawpoolsri S; Stepniewska K; Sapchookul P; Puthavathana P; Fukuda C; Lindegardh N; Tarning J; White NJ; Day N; Taylor WR
    J Antimicrob Chemother; 2013 Mar; 68(3):697-707. PubMed ID: 23143901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
    Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
    Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
    Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
    Beigel JH; Bao Y; Beeler J; Manosuthi W; Slandzicki A; Dar SM; Panuto J; Beasley RL; Perez-Patrigeon S; Suwanpimolkul G; Losso MH; McClure N; Bozzolo DR; Myers C; Holley HP; Hoopes J; Lane HC; Hughes MD; Davey RT;
    Lancet Infect Dis; 2017 Dec; 17(12):1255-1265. PubMed ID: 28958678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
    Sugaya N; Ohashi Y
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2575-82. PubMed ID: 20368393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuraminidase inhibitors for preventing and treating influenza in adults and children.
    Jefferson T; Jones MA; Doshi P; Del Mar CB; Hama R; Thompson MJ; Spencer EA; Onakpoya I; Mahtani KR; Nunan D; Howick J; Heneghan CJ
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD008965. PubMed ID: 24718923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral drugs for seasonal influenza 2014-2015.
    Med Lett Drugs Ther; 2014; 56(1457):121-3. PubMed ID: 25423066
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
    Watanabe A; Chang SC; Kim MJ; Chu DW; Ohashi Y;
    Clin Infect Dis; 2010 Nov; 51(10):1167-75. PubMed ID: 20936975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.
    Heneghan CJ; Onakpoya I; Jones MA; Doshi P; Del Mar CB; Hama R; Thompson MJ; Spencer EA; Mahtani KR; Nunan D; Howick J; Jefferson T
    Health Technol Assess; 2016 May; 20(42):1-242. PubMed ID: 27246259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Trujillo A; Barnes J; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2015 Jun; 15(6):654-62. PubMed ID: 25788164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population.
    Ambrozaitis A; Gravenstein S; van Essen GA; Rubinstein E; Balciuniene L; Stikleryte A; Crawford C; Elliott M; Shult P
    J Am Med Dir Assoc; 2005; 6(6):367-74. PubMed ID: 16286057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial.
    South East Asia Infectious Disease Clinical Research Network
    BMJ; 2013 May; 346():f3039. PubMed ID: 23723457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled Zanamivir vs Oral Oseltamivir to Prevent Influenza-related Hospitalization or Death: A Nationwide Population-based Quasi-experimental Study.
    Su CP; Chan KA; Huang CT; Fang CT
    Clin Infect Dis; 2022 Oct; 75(8):1273-1279. PubMed ID: 35299245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.
    Lancet; 1998 Dec; 352(9144):1877-81. PubMed ID: 9863784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
    Treanor JJ; Hayden FG; Vrooman PS; Barbarash R; Bettis R; Riff D; Singh S; Kinnersley N; Ward P; Mills RG
    JAMA; 2000 Feb; 283(8):1016-24. PubMed ID: 10697061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.